Abstract: A bed is provided. The bed includes a plurality of wheels contacting the floor, a frame supported by the plurality of wheels, a support deck supported by the frame and having a head end, a foot end, a first side extending between the head end to the foot end, and a second side extending between the head end to the foot end, the support deck being expandable in a transverse extent from the first side to the second side from a first size to a second size, the second size having a larger area than the first size, and an assembly coupled to the support deck, the assembly including a single powered mechanical actuator which expands the support deck from the first size to the second size.

Abstract: Provided are electric vehicle charging systems (EV charging systems) and methods of operating such systems for charging electric vehicles (EVs). A system, which may be referred to as electric vehicle service equipment (EVSE), comprises one or more EV charging ports (e.g., charge handles) for connecting to EVs. The system may include various features to identify specific EVs. The system also includes a grid connector for connecting to an external power grid and, in some examples, to monitor the power grid conditions (e.g., voltage, AC frequency). The system also includes a system controller, configured to control the power output at each EV charging port based on, e.g., vehicle charging requirements and/or available grid power. The system can also include an integrated battery, serving as a backup and/or an addition to the power grid. Furthermore, in some examples, the system includes a solar connector (e.g., with an integrated inverter) for connection to an external solar array.

Abstract: The present invention relates to a pharmaceutical formulation comprising the drug 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one in a solid dispersion with a matrix polymer that exhibits low hygroscopicity and high softening temperature, such as copovidone. The invention also relates to a daily pharmaceutical dose of the drug provided by such a formulation. In addition, the invention relates to the use of a matrix polymer that exhibits low hygroscopicity and high softening temperature in solid dispersion with 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one for increasing the bioavailability of the drug.

Abstract: A system for identifying irregularities in behaviors of a non-human animal, the system comprising a processing circuitry configured to: provide a behavioral baseline including first information on regular behaviors of the non-human animal over a given period of time when no irregularities occur; obtain data on a series of consecutively identified behaviors of the non-human animal identified over a second period of time; perform an action upon the data not complying with the behavioral baseline, thereby indicating an irregularity in the non-human animal behavior.

Abstract: A bed is provided. The bed may include a lift system which raises and lowers a support deck of the bed. The lift system may include multiple individually actuatable lift systems. The bed may include an expandable support deck. The bed may include a powered caster braking system.

Abstract: A control system controls tenant services to various tenants by obtaining tenant attributes for each tenant, with respect to a particular workload. A model is generated that models tenant usage performance for a set of best performing tenants. The model is then applied to a remainder of the tenants to obtain a metric indicative of a likely tenant capacity for incremental usage of the workload. The control system controls the services provided to the tenant based upon the likelihood of adoption metric.

Abstract: An ear-wearable electronic device includes a first near-field communication (NFC) device and a transfer region configured to facilitate transfer of a wearable sensor unit into an ear of a wearer or onto an outer ear of the wearer or a surface of the wearer's head adjacent the outer ear. The wearable sensor unit comprises electronic circuitry comprising a second NFC device configured to communicatively couple to the first NFC device and facilitate wireless transfer of power from the ear-wearable electronic device to the wearable sensor unit and wireless transfer of data at least from the wearable sensor unit to the ear-wearable electronic device, and one or more sensors configured to measure at least one physiologic parameter or physiologic condition of the wearer. The wearable sensor unit and the ear-wearable electronic device are configured to remain mechanically decoupled from one another subsequent to deployment of the wearable sensor unit.

Abstract: The present invention relates to a pharmaceutical formulation comprising the drug 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one in a solid dispersion with a matrix polymer that exhibits low hygroscopicity and high softening temperature, such as copovidone. The invention also relates to a daily pharmaceutical dose of the drug provided by such a formulation. In addition, the invention relates to the use of a matrix polymer that exhibits low hygroscopicity and high softening temperature in solid dispersion with 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one for increasing the bioavailability of the drug.

Abstract: The present invention relates to a pharmaceutical formulation comprising the drug 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one in a solid dispersion with a matrix polymer that exhibits low hygroscopicity and high softening temperature, such as copovidone. The invention also relates to a daily pharmaceutical dose of the drug provided by such a formulation. In addition, the invention relates to the use of a matrix polymer that exhibits low hygroscopicity and high softening temperature in solid dispersion with 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one for increasing the bioavailability of the drug.

Abstract: An ear-worn electronic device comprises a housing configured to fit at least partially in an ear of a wearer, a power source situated in the housing, and a temperature sensor arrangement situated in or on the housing and coupled to the power source. The temperature sensor arrangement is configured to generate sensor signals in response to heat generated in the wearer's ear and a controller, situated in the housing and coupled to the power source and the temperature sensor arrangement, is configured to assess a fit of the device using the sensor signals.

Abstract: An image processing apparatus, comprising: an input unit configured to receive one or more images of a face of a user and one or more images of a face of a virtual avatar; a determining unit configured to determine, based on one or more of the images of the face of the user and one or more of the images of the face of the virtual avatar, a match score indicating a degree of resemblance between the face of the user and the face of the virtual avatar; an evaluation unit configured to evaluate whether the determined match score meets or exceeds a first threshold match score; and an output unit configured to output, for display, a virtual element associated with the virtual avatar that is responsive to whether the determined match score meets or exceeds the first threshold match score.

Abstract: An ear-wearable device includes a photoplethysmography (PPG) sensor. One or more processors of the ear-wearable device are configured to determine, based on sample values of a PPG signal generated by the PPG sensor, whether a user of the ear-wearable device has fallen.

Abstract: A hearing device adapted for use by a wearer comprises an audio streaming circuit configured to receive electromagnetic audio streaming via a first communication link. A configuration circuit is configured to receive configuration parameters via a second communication link different from the first communication link for configuring the hearing device to receive the electromagnetic audio streaming. Control circuitry of the hearing device configures the hearing device to enable reception of the electromagnetic audio streaming in accordance with the received configuration parameters.

Abstract: A method is a described for constructing a hearing aid shell that comprises a combination of hard and soft materials. In one embodiment, 3D printing is combined with conventional mold/casting methods so that a first shell portion made of a hard material and a mold for a second shell portion are 3D printed. The mold is then filled with a soft material which is allowed to set to form the second shell portion, and the first and second shell portions are adhesively attached.

Abstract: A device controls a power flow in an AC network and has a series converter with a DC side to connect to a DC link and an AC side to connect to the AC network via a series transformer. The device further has a bridging arrangement between the series transformer and the series converter configured to bridge the series converter. The bridging arrangement contains at least one bridging branch having a switching unit with antiparallel thyristors and a resistance in series with the switching unit. Furthermore, a method of operation operates the device.

Abstract: Various embodiments of a hearing device and a method of using such device are disclosed. The hearing device includes a housing having an inner surface and an outer surface, electronic components disposed within the housing, and a port disposed in the housing and extending between a first end at the outer surface of the housing and a second end disposed within the housing, where the port is acoustically connected to at least one of a speaker or a microphone of the electronic components. The hearing components also include a controller that is electrically connected to a sensor and that is adapted to detect a change in capacitance of the sensor, where the change in capacitance is associated with debris at least partially occluding the port.

Abstract: A hearing device adapted for use by a wearer comprises an audio streaming circuit configured to receive electromagnetic audio streaming via a first communication link. A configuration circuit is configured to receive configuration parameters via a second communication link different from the first communication link for configuring the hearing device to receive the electromagnetic audio streaming. Control circuitry of the hearing device configures the hearing device to enable reception of the electromagnetic audio streaming in accordance with the received configuration parameters.

Abstract: The present invention relates to a pharmaceutical formulation comprising the drug 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one in a solid dispersion with a matrix polymer that exhibits low hygroscopicity and high softening temperature, such as copovidone. The invention also relates to a daily pharmaceutical dose of the drug provided by such a formulation. In addition, the invention relates to the use of a matrix polymer that exhibits low hygroscopicity and high softening temperature in solid dispersion with 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one for increasing the bioavailability of the drug.

Abstract: An ear-wearable electronic device has a shell with an outer surface. A mounting void goes through the outer surface of the shell and exposes an internal volume of the shell. The mounting void is located at an ear-contacting region of the shell. The ear-wearable device includes a photoplethysmography sensor assembly having an optical transmission structure mounted in the mounting void and having a distal end exposed proximate the outer surface. The distal end of the optical transmission structure conforms to the outer surface of the shell at the ear-contacting region. The distal end is in contact with ear tissue of a user of the ear-wearable electronic device during use.

Abstract: A method of reducing execution jitter includes a processor having several cores and control logic that receives core configuration parameters. Control logic determines if a first set of cores are selected to be disabled. If none of the cores is selected to be disabled, the control logic determines if a second set of cores is selected to be jitter controlled. If the second set of cores is selected to be jitter controlled, the second set of cores is set to a first operating state. If the first set of cores is selected to be disabled, the control logic determines a second operating state for a third set of enabled cores. The control logic determines if the third set of enabled cores is jitter controlled, and if the third set of enabled cores is jitter controlled, the control logic sets the third set of enabled cores to the second operating state.